Physician profile
Barbara Nelson
NPI 1609462746
$3,646.25
in general payments reported to CMS, 2019-2025
25 companies · $794 in 2025
The $794 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,037 · 2023: $929 · 2024: $886 · 2025: $794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,610.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,609.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $749.73 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $464.88 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $448.81 | 2022-2025 | |
| Abbvie INC. | $440.37 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $211.63 | 2022-2025 | Jardiance, Tradjenta |
| Glaxosmithkline, LLC. | $162.62 | 2022-2025 | Shingrix, Arexvy, Bexsero |
| Astrazeneca Pharmaceuticals LP | $156.01 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Exact Sciences Corporation | $140.03 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Gilead Sciences, INC. | $123.14 | 2025 | Livdelzi |
| Dexcom, INC. | $105.98 | 2024-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $103.36 | 2022-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $91.48 | 2022-2025 | Eliquis, Camzyos |
| Astellas Pharma US INC | $82.27 | 2023-2024 | Veozah |
| Kowa Pharmaceuticals America, INC. | $53.09 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $48.03 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $44.95 | 2023 | Intellis Adaptivestim |
| Dynavax Technologies Corporation | $41.40 | 2022-2023 | Heplisav-B |
| Axsome Therapeutics, INC. | $36.25 | 2024-2025 | Sunosi |
| Bayer Healthcare Pharmaceuticals INC. | $28.57 | 2025 | |
| Vbi Vaccine (Delaware) INC. | $27.28 | 2022 | |
| Sumitomo Pharma America, INC. | $24.46 | 2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.40 | 2024 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $17.41 | 2025 | |
| Idorsia Pharmaceuticals US INC | $13.07 | 2024 | Quviviq |
| Tms Neurohealth Centers INC. | $13.03 | 2025 | Tms Neurohealth Centers INC. |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.